Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 8/20 | 0.54 |
| ▸ | DRD2 | P14416 | 3/20 | 0.53 |
| ▸ | HTR2C | P28335 | 3/20 | 0.53 |
| ▸ | DRD3 | P35462 | 3/20 | 0.53 |
| ▸ | HTR6 | P50406 | 3/20 | 0.53 |
| ▸ | HTR2A | P28223 | 2/20 | 0.53 |
| ▸ | MMP1 | P03956 | 2/20 | 0.48 |
| ▸ | GHSR | Q92847 | 2/20 | 0.44 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.43 |
| ▸ | STS | P08842 | 3/20 | 0.43 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.43 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6365337 | 0.87 | DRD2 (0.55) | MMP13DRD2HTR2CDRD3HTR6 | |
| SCHEMBL5727550 | 0.86 | DRD2 (0.71) | DRD2HTR2CDRD3HTR6HTR2A | |
| SCHEMBL6365550 | 0.83 | SLC2A1 (0.65) | MMP13DRD2HTR2CDRD3HTR6 | |
| SCHEMBL5727922 | 0.80 | DRD2 (0.59) | DRD2HTR2CDRD3HTR6HTR2A | |
| SCHEMBL6371443 | 0.78 | HTR6 (0.53) | MMP13DRD2HTR2CDRD3HTR6 | |
| SCHEMBL5727521 | 0.78 | DRD2 (0.58) | MMP13DRD2HTR2CDRD3HTR6 | |
| SCHEMBL5782537 | 0.77 | ACLY (0.48) | DRD2HTR2CDRD3HTR6HTR2A | |
| SCHEMBL5727648 | 0.77 | DRD2 (0.57) | DRD2HTR2CDRD3HTR6HTR2A | |
| SCHEMBL5726744 | 0.77 | DRD2 (0.57) | DRD2HTR2CDRD3HTR6HTR2A | |
| SCHEMBL5726862 | 0.76 | HTR6 (0.54) | MMP13DRD2HTR2CDRD3HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7122538-B2 | Sulfonamide derivatives as antipsychotic agents | GLAXO GROUP LIMITED (GB) | 2006-10-17 | — | — | US | disclosed |
| EP-1549639-B1 | SULPHONAMIDE DERIVATIVES AS ANTIPSYCHOTIC AGENTS | GLAXO GROUP LTD (GB) | 2006-05-24 | — | — | EP | disclosed |
| US-20060063757-A1 | Sulfonamide derivatives as antipsychotic agents | GLAXO GROUP LIMITED (GB) | 2006-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063757-A1 | Sulfonamide derivatives as antipsychotic agents | SIGMAR1, CHRM1, NPSR1 | MMP13 3964/4885DRD2 80/4885HTR2C 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.